Zentalis Pharmaceuticals Inc
ZNTL1.375USD
+0.035+2.61%
시장 운영 시간 （ET）시세는 15분 지연됩니다
98.93M시가총액
손실P/E TTM
자세한 내용은 Zentalis Pharmaceuticals Inc 회사
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
회사 정보
종목 코드 ZNTL
회사 이름Zentalis Pharmaceuticals Inc
상장일Apr 03, 2020
CEOMs. Julie Eastland
직원 수166
유형Ordinary Share
회계 연도 종료Apr 03
주소10275 Science Center Drive
도시SAN DIEGO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호92121
전화18582634333
웹사이트https://www.zentalis.com/
종목 코드 ZNTL
상장일Apr 03, 2020
CEOMs. Julie Eastland
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
수익 분석
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
데이터 없음
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 23
마지막 업데이트: Wed, Jul 23
주주
주주 유형
주주
주주
비율
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
주주
주주
비율
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
33.53%
Investment Advisor
20.08%
Hedge Fund
18.52%
Individual Investor
12.74%
Research Firm
4.62%
Venture Capital
3.66%
Corporation
1.33%
Endowment Fund
0.24%
Family Office
0.13%
Other
5.14%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
373
68.31M
94.93%
-22.23M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
2023Q1
342
70.12M
118.05%
-6.08M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Matrix Capital Management Company, LP
13.96M
19.4%
--
--
Mar 31, 2025
Walters (William T)
7.05M
9.8%
+3.05M
+76.25%
Jan 29, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.33%
-10.27K
-0.27%
Mar 31, 2025
The Vanguard Group, Inc.
3.26M
4.53%
-10.63K
-0.32%
Mar 31, 2025
Millennium Management LLC
3.07M
4.27%
-711.78K
-18.82%
Mar 31, 2025
Acadian Asset Management LLC
2.67M
3.72%
+1.61M
+150.56%
Mar 31, 2025
Decheng Capital LLC
2.02M
2.81%
-318.33K
-13.62%
Mar 31, 2025
Opaleye Management Inc.
1.99M
2.76%
+217.50K
+12.31%
Mar 31, 2025
Almitas Capital LLC
1.71M
2.38%
+84.03K
+5.16%
Mar 31, 2025
Tang Capital Management, LLC
1.50M
2.08%
+1.50M
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Federated Hermes MDT Small Cap Core ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity Growth Opportunities ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
더 보기
Federated Hermes MDT Small Cap Core ETF
비율0.07%
Invesco RAFI US 1500 Small-Mid ETF
비율0.01%
iShares Micro-Cap ETF
비율0.01%
Fidelity Enhanced Small Cap ETF
비율0.01%
Invesco Nasdaq Biotechnology ETF
비율0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0%
Fidelity Growth Opportunities ETF
비율0%
T Rowe Price Small-Mid Cap ETF
비율0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0%
ProShares Ultra Nasdaq Biotechnology
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
